FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981244023> ?p ?o ?g. }

• W2981244023 abstract "Abstract Abstract 527 Background: Rozrolimupab is the first in-class fully human, recombinant antibody mixture for the treatment of ITP. Rozrolimupab comprises 25 unique human antibodies with documented binding capacity to the Rhesus D antigen on red blood cells, and constitutes a promising, modern counter-part to the blood-derived immunoglobulin products currently used in the treatment of ITP. The antibody mixture constituting rozrolimupab is produced by a novel single batch manufacturing strategy. Objectives and Endpoints: The objectives of the trial were to investigate the safety and efficacy of a single dose of rozrolimupab in RhD positive, non-splenectomized adult patients with primary ITP. The primary endpoint was incidence and severity of Adverse Events (AEs) during the 6-week trial period. Secondary endpoints included identification of the optimal dose of rozrolimupab and percentage of patients responding to treatment at 72 hours, 7 and 15 days. Methods: Patients from 27 sites in 11 countries were enrolled in this dose escalation (75 μg/kg – 300 μg/kg), multicentre, open label trial. Inclusion criteria included confirmed presence of thrombocytopenia with two individual pre-dose platelet counts of < 30 × 109/L. The patients received a single iv dose of rozrolimupab, and were followed for 6 weeks with frequent evaluations for safety and efficacy. Response was defined as platelet count ≥ 30 ×109/L and increase in platelet count from baseline by > 20 × 109/L. Results: A total of 61 ITP patients were treated with rozrolimupab: 75 μg/kg (11 patients), 100 μg/kg (10 patients), 125 μg/kg (10 patients), 150 μg/kg (5 patients), 200 μg/kg (6 patients), 250 μg/kg (6 patients) and 300 μg/kg (13 patients). Data from the 300 μg/kg cohort were not available for this abstract, but will be included in the final presentation.Given the small size of this study, the dose cohorts differed in a number of baseline characteristics. 60–90% of patients were females in all dose cohorts except in the 75 μg/kg cohort where 73% were males. Median platelet count before trial entry ranged from 11.5 to 22.3 × 109/L, and median time from first ITP diagnosis ranged from 5 to 68 months. In the individual dose groups, up to 83% of the patients responded at day 7. Up to 50% and 60% of the patients responded at 24 and 72 hours, respectively, and some responses lasted for the duration of the 6 weeks follow up period. Platelet responses also included patients who had baseline platelet counts below 10 ×109/L. A total of 51 AEs considered related to trial drug were reported in 20 patients. The most frequently reported adverse reactions were headache (7 events in 5 patients) and pyrexia (5 events in 4 patients). All but 2 of the adverse reactions (one headache, one extravascular haemolysis) were of mild or moderate intensity. Four of the 51 adverse reactions were categorized as Serious Adverse Events: One mild haemoglobin decrease in the 100 μg/kg cohort, one extravascular haemolysis in the 200 μg/kg cohort (mentioned above) and two mild to moderate, transient increases in D-dimer with no clinical symptoms in the 250 μg/kg cohort. Laboratory data showed a mean maximum decrease in haemoglobin ranging from 1.1 g/dL to 2.7 g/dL in individual cohorts with a slight dose dependency. A drop in haemoglobin of ≥ 3 g/dL was seen in 2 patients, one of 3.1 g/dL in the 100 μg/kg cohort and one of 4.5 g/dL in the 200 μg/kg cohort. Conclusions: Rozrolimupab is well tolerated with a favourable safety profile. In the individual dose groups, up to 83% of patients responded at day 7 including patients who had baseline platelet counts below 10 ×109/L. Final safety and efficacy data from all dose groups in the completed Phase II trial of rozrolimupab in primary ITP patients will be presented. Disclosures: Wiktor-Jedrzejczak: Celgene: Honoraria; Janssen-Cilag: Honoraria; Novartis: Honoraria, Research Funding. Flensburg:Symphogen: Employment. Petersen:Symphogen: Employment." @default.
• W2981244023 created "2019-10-25" @default.
• W2981244023 creator A5005053658 @default.
• W2981244023 creator A5005866361 @default.
• W2981244023 creator A5006182201 @default.
• W2981244023 creator A5008703895 @default.
• W2981244023 creator A5008779503 @default.
• W2981244023 creator A5010243866 @default.
• W2981244023 creator A5015173296 @default.
• W2981244023 creator A5016197132 @default.
• W2981244023 creator A5016306582 @default.
• W2981244023 creator A5018824481 @default.
• W2981244023 creator A5025857936 @default.
• W2981244023 creator A5026322585 @default.
• W2981244023 creator A5028309658 @default.
• W2981244023 creator A5035337309 @default.
• W2981244023 creator A5037382125 @default.
• W2981244023 creator A5042924687 @default.
• W2981244023 creator A5044841069 @default.
• W2981244023 creator A5048032270 @default.
• W2981244023 creator A5048998886 @default.
• W2981244023 creator A5051306233 @default.
• W2981244023 creator A5054239434 @default.
• W2981244023 creator A5054816508 @default.
• W2981244023 creator A5058355502 @default.
• W2981244023 creator A5061299820 @default.
• W2981244023 creator A5069303553 @default.
• W2981244023 creator A5069332579 @default.
• W2981244023 creator A5074486986 @default.
• W2981244023 creator A5076914273 @default.
• W2981244023 creator A5080469438 @default.
• W2981244023 creator A5087052731 @default.
• W2981244023 creator A5089310648 @default.
• W2981244023 creator A5089578564 @default.
• W2981244023 date "2011-11-18" @default.
• W2981244023 modified "2023-10-02" @default.
• W2981244023 title "Final Results From a Phase II Trial with the First in Class Recombinant Polyclonal Antibody Product Rozrolimupab in Primary Immune Thrombocytopenia" @default.
• W2981244023 doi "https://doi.org/10.1182/blood.v118.21.527.527" @default.
• W2981244023 hasPublicationYear "2011" @default.
• W2981244023 type Work @default.
• W2981244023 sameAs 2981244023 @default.
• W2981244023 citedByCount "2" @default.
• W2981244023 countsByYear W29812440232012 @default.
• W2981244023 crossrefType "journal-article" @default.
• W2981244023 hasAuthorship W2981244023A5005053658 @default.
• W2981244023 hasAuthorship W2981244023A5005866361 @default.
• W2981244023 hasAuthorship W2981244023A5006182201 @default.
• W2981244023 hasAuthorship W2981244023A5008703895 @default.
• W2981244023 hasAuthorship W2981244023A5008779503 @default.
• W2981244023 hasAuthorship W2981244023A5010243866 @default.
• W2981244023 hasAuthorship W2981244023A5015173296 @default.
• W2981244023 hasAuthorship W2981244023A5016197132 @default.
• W2981244023 hasAuthorship W2981244023A5016306582 @default.
• W2981244023 hasAuthorship W2981244023A5018824481 @default.
• W2981244023 hasAuthorship W2981244023A5025857936 @default.
• W2981244023 hasAuthorship W2981244023A5026322585 @default.
• W2981244023 hasAuthorship W2981244023A5028309658 @default.
• W2981244023 hasAuthorship W2981244023A5035337309 @default.
• W2981244023 hasAuthorship W2981244023A5037382125 @default.
• W2981244023 hasAuthorship W2981244023A5042924687 @default.
• W2981244023 hasAuthorship W2981244023A5044841069 @default.
• W2981244023 hasAuthorship W2981244023A5048032270 @default.
• W2981244023 hasAuthorship W2981244023A5048998886 @default.
• W2981244023 hasAuthorship W2981244023A5051306233 @default.
• W2981244023 hasAuthorship W2981244023A5054239434 @default.
• W2981244023 hasAuthorship W2981244023A5054816508 @default.
• W2981244023 hasAuthorship W2981244023A5058355502 @default.
• W2981244023 hasAuthorship W2981244023A5061299820 @default.
• W2981244023 hasAuthorship W2981244023A5069303553 @default.
• W2981244023 hasAuthorship W2981244023A5069332579 @default.
• W2981244023 hasAuthorship W2981244023A5074486986 @default.
• W2981244023 hasAuthorship W2981244023A5076914273 @default.
• W2981244023 hasAuthorship W2981244023A5080469438 @default.
• W2981244023 hasAuthorship W2981244023A5087052731 @default.
• W2981244023 hasAuthorship W2981244023A5089310648 @default.
• W2981244023 hasAuthorship W2981244023A5089578564 @default.
• W2981244023 hasConcept C120665830 @default.
• W2981244023 hasConcept C121332964 @default.
• W2981244023 hasConcept C126322002 @default.
• W2981244023 hasConcept C159654299 @default.
• W2981244023 hasConcept C197934379 @default.
• W2981244023 hasConcept C203014093 @default.
• W2981244023 hasConcept C203092338 @default.
• W2981244023 hasConcept C535046627 @default.
• W2981244023 hasConcept C61511704 @default.
• W2981244023 hasConcept C71924100 @default.
• W2981244023 hasConcept C89560881 @default.
• W2981244023 hasConcept C90924648 @default.
• W2981244023 hasConceptScore W2981244023C120665830 @default.
• W2981244023 hasConceptScore W2981244023C121332964 @default.
• W2981244023 hasConceptScore W2981244023C126322002 @default.
• W2981244023 hasConceptScore W2981244023C159654299 @default.
• W2981244023 hasConceptScore W2981244023C197934379 @default.
• W2981244023 hasConceptScore W2981244023C203014093 @default.
• W2981244023 hasConceptScore W2981244023C203092338 @default.
• W2981244023 hasConceptScore W2981244023C535046627 @default.
• W2981244023 hasConceptScore W2981244023C61511704 @default.
• W2981244023 hasConceptScore W2981244023C71924100 @default.
• W2981244023 hasConceptScore W2981244023C89560881 @default.
• W2981244023 hasConceptScore W2981244023C90924648 @default.

• next